Following frantic speculation since the USA announced new tax regulations aimed at preventing tax inversion orientated M&A activity, the biggest pharmaceutical acquisition deal in history, has been terminated.
As was widely forecast, US pharma giant Pfizer (NYSE: PFE) this morning announced that it will not proceed with its planned $160 billion acquisition of Ireland-domiciled Allergan (NYSE: AGN). This is Pfizer’s second aborted attempt at a tax-inversion directed acquisition; in 2014, after company and political objections, it gave up on its $69 billion (~$98 billion at current exchange rates) takeover of Anglo-Swedish pharma major AstraZeneca.
Pfizer’s shares rose 1% in pre-market opening trading in the USA, percent in trading before the, while Allergan declined less than 1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze